menu search

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...

November 4, 2023, 5:37 pm

Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate...

November 4, 2023, 12:00 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...

November 3, 2023, 11:30 pm

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...

November 3, 2023, 8:01 pm

Actinium pharmaceuticals: the trickle down continues, and i maintain a buy

Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. Th...

November 3, 2023, 6:08 pm

Protara therapeutics announces third quarter 2023 financial results and business update

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preli...

November 3, 2023, 12:00 pm

Galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of bela...

November 3, 2023, 12:00 pm

Morphic announces corporate highlights and financial results for the third quarter 2023

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative...

November 3, 2023, 11:00 am

Why is werewolf therapeutics (howl) stock up 20% today?

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This...

November 3, 2023, 10:26 am

Cidara therapeutics provides corporate update and reports third quarter 2023 financial results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapi...

November 2, 2023, 8:15 pm

Pantheon vision raises $2.5 million in seed funding to launch development of bioengineered corneal implant

The medical device startup is focused on addressing significant unmet needs of patients suffering from ...

November 2, 2023, 6:06 pm

Genfit to present update on scientific and corporate progress at the liver meeting® 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage bio...

November 2, 2023, 5:10 pm

Assertio holdings, inc. to release third quarter 2023 financial results on november 8, 2023

LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharma...

November 2, 2023, 4:06 pm

Inari medical to present at upcoming investor conferences

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat a...

November 2, 2023, 4:01 pm

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in pa...

November 2, 2023, 1:17 pm


Search within

Pages Search Results: